FDA/CDC

CDC supports Ebola response in DRC


 

The Centers for Disease Control and Prevention has been working with the Ministry of Health of the Democratic Republic of the Congo (DRC) on a new Ebola outbreak reported on Aug, 1, 2018, in North Kivu province.

CDC News icon

“For the current outbreak, CDC has deployed experienced Ebola experts to DRC and the World Health Organization [WHO] to provide guidance on coordination of outbreak response, laboratory testing, disease contact tracing, infection control, and health communication,” according to a CDC press release.

The CDC’s online response also provides a Traveler’s Health notice of Watch Level 1 for the DRC, which advises standard precautions and avoiding infected individuals, but not an advisory against travel.

Region of the Democratic Republic of the Congo where the August 2018 ebolavirus outbreak is occurring. CDC

Region of the Democratic Republic of the Congo where the August 2018 ebolavirus outbreak is occurring.

The Ebola virus associated with the current outbreak is Zaire ebolavirus, according to genetic testing by scientists in the DRC. This is the same species that caused an outbreak earlier this year in Equateur province in northwestern DRC, although differences between the genes of the viruses suggest the two outbreaks are not linked, according to the CDC media announcement.

As of Aug. 12, 2018, the following statistics were reported by the WHO on the outbreak:

  • Confirmed cases: 30
  • Probable cases: 27
  • Total cases: 57
  • Deaths: 41 (14 confirmed, 27 probable)

The outbreak is of particular concern because of the instability of the area, which hampers relief and quarantine efforts. The outbreak is in a part of the country identified by the U.S. State Department as a “restricted travel” zone due to armed conflict and violence targeting civilians, according to the CDC.

Recommended Reading

Study: No link between non-Hodgkin lymphoma and Q fever
MDedge Infectious Disease
Blood type A linked to more-severe diarrhea
MDedge Infectious Disease
NIH launches early Ebola treatment trial
MDedge Infectious Disease
FDA issues Ebola preparedness statement
MDedge Infectious Disease
Oral tecovirimat for smallpox shows efficacy in animals, safety in humans
MDedge Infectious Disease
Cost is high for Japanese encephalitis vaccinations
MDedge Infectious Disease
Primary efficacy not met by new M. tuberculosis vaccine strategies
MDedge Infectious Disease
Mosaic HIV-1 vaccine stimulates broad antigenicity, enters phase 2b human efficacy trial
MDedge Infectious Disease
Female survivor transmits Ebola virus 1 year after outbreak
MDedge Infectious Disease
FDA: Krintafel approved as ‘radical cure’ for preventing malaria relapse
MDedge Infectious Disease